HIV Infections Clinical Trial
Official title:
Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex
To determine the following about the use of SC-48334 in patients with AIDS and advanced AIDS
related complex (ARC):
1. The largest maximum tolerated dose (MTD); 2. Effectiveness against HIV; 3.
Pharmacokinetics - how fast SC-48334 reaches the bloodstream, what concentration is reached,
and how long it remains in the patient's blood.
SC-48334 is a chemical that prevents the biochemical actions of certain enzymes in the body,
and recent studies have shown that it may also prevent the activity of HIV. The study will
attempt to show whether SC-48334 can safely and effectively break the cycle of HIV infection
in AIDS and advanced ARC by progressively eliminating HIV.
SC-48334 is a chemical that prevents the biochemical actions of certain enzymes in the body,
and recent studies have shown that it may also prevent the activity of HIV. The study will
attempt to show whether SC-48334 can safely and effectively break the cycle of HIV infection
in AIDS and advanced ARC by progressively eliminating HIV.
Six patients are enrolled sequentially into each of eight different dose levels and the drug
is administered by mouth at least 60 minutes before meals according to the following
schedule: Day 1: One-quarter of total assigned daily dose. Patients receive the dosage in
the hospital as either an inpatient or outpatient and are observed for 12 hours, during
which time they are evaluated and blood is drawn for pharmacokinetic studies. Patients
return at 24 and 48 hours for a limited physical examination and additional pharmacokinetic
studies. Days 4 - 31: Total assigned daily dose, one-quarter 4 times a day. Patients are
observed for at least 5 days in the hospital following the start of this part of the
program, during which time clinical, laboratory, and pharmacokinetic information is obtained
in order to establish baseline values. After the 6th day, patients are evaluated with a
complete physical exam, urinalysis, and laboratory studies once a week and a limited
physical exam and brief laboratory studies 3 times a week. At each of the eight dose levels,
the second and third patients receive their first dose only after the first patient has been
followed for 72 hours after receiving the first dose. Patients 4, 5, and 6 begin treatment
only after patients 2 and 3 have completed 14 days of the four-part total dose. Patients are
treated on an outpatient basis, with 5 to 6 days spent in the hospital for evaluation.
;
Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |